News

Following the approval for sNDA, the capsules’ labeling will feature clinical safety and efficacy data for Vancocin in treating currently circulating strains of Clostridium difficile, including the BI/NAP1

The collaboration will help various countries across the globe in making them self-sufficient in the manufacture of vital biopharmaceuticals such as vaccines, insulin and biosimilars, thus reducing the

Kymos plans to take up research activities in a new immunology laboratory that will be opened in the Barcelona Science Park (PCB) in early January 2012, conducting regulatory

The system with dendrimers, is believed to deliver steroids into the targeted cells that cause neuroinflammation damage, which in turn leads to retinitis pigmentosa and can ultimately cause

The company has received funds worth £450,000 from Finance Wales, Acceleris, Welsh Government and Denbighshire County Council, which would support its entry into the next phase of development,

The Phase 1 study involved 32 patients with either acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL), and will determine the maximum tolerated dose (MTD), dose limiting

ATX-101, an injectable drug being studied for the reduction of localized fat is a proprietary formulation of deoxycholate, an endogenous compound that is present in the body to

The collaboration signed in December 2009, has been extended to an additional year through December 2012. Initially Bristol-Myers Squibb paid NeurOp a licensing fee of $1.5m and agreed

The two randomized double-blind placebo-controlled trials Phase III efficacy trials- BLOOM-1 and BLOOM-2 enrolled 597 and 575 surgically menopausal women, respectively, for six-months of therapy. In the BLOOM-1